睑板腺癌的治疗研究进展  

Research progress in treatment of meibomian adenocarcinoma

作　　者：黄文停(综述) 刘慧霞(审校)[1] 倪梦圆 HUANG Wenting;LIU Huixia;NI Mengyuan(Department of Ophthalmology,Anhui Provincial General Hospital of the Armed Police,Hefei,Anhui 230041,China)

机构地区：[1]武警安徽省总队医院眼科,安徽合肥230041

出　　处：《现代医药卫生》2023年第22期3921-3924,3930,共5页Journal of Modern Medicine & Health

摘　　要：睑板腺癌是源于机体睑板腺和睫毛的皮脂腺癌,位居我国眼睑恶性肿瘤第2位,发病率仅次于基底细胞癌。由于其易误诊、高复发、局部扩散及远处转移的特点,早期诊断及治疗对患者尤为重要。目前,睑板腺癌的治疗仍以手术为主,但随着手术及放射治疗方式的改进、相关基因的发现、局部化学治疗药物的使用,以及光动力疗法的出现,睑板腺癌的治疗选择方式越来越多。该文就近年来国内外睑板腺癌的治疗研究进展进行综述。Meibomian adenocarcinoma is a sebaceous gland cancer originating from meibomian gland and eyelashes,ranking second in eyelid malignant tumor in China,and its incidence is second only to basal cell carcinoma.Due to its characteristics of easy misdiagnosis,high recurrence,local spread and distant metastasis,early diagnosis and treatment are particularly important for patients.At present,surgery is still the main treatment for meibomian adenocarcinoma.However,with the improvement of surgery and radiotherapy,the discovery of related genes,the use of local chemotherapy drugs and the emergence of photodynamic therapy,the treatment options for meibomian adenocarcinoma are increasing.This article reviews the research progress in treatment progress of meibomian adenocarcinoma at home and abroad in recent years.

关 键 词：睑板腺癌 治疗 眼睑重建 综述 

分 类 号：R739.7[医药卫生—肿瘤]